Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fibromatosis, Aggressive | 5 | 2023 | 109 | 1.460 |
Why?
|
| Sarcoma | 10 | 2023 | 1725 | 1.340 |
Why?
|
| Soft Tissue Neoplasms | 5 | 2023 | 882 | 0.660 |
Why?
|
| Dioxoles | 1 | 2017 | 19 | 0.610 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2017 | 24 | 0.600 |
Why?
|
| Ketones | 1 | 2017 | 54 | 0.590 |
Why?
|
| Furans | 1 | 2017 | 104 | 0.590 |
Why?
|
| Sarcoma, Ewing | 4 | 2022 | 406 | 0.530 |
Why?
|
| Bone Neoplasms | 6 | 2023 | 2576 | 0.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2021 | 15862 | 0.460 |
Why?
|
| Indazoles | 3 | 2021 | 297 | 0.250 |
Why?
|
| Sarcoma, Small Cell | 1 | 2023 | 5 | 0.230 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2023 | 116 | 0.210 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2023 | 75 | 0.210 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 14289 | 0.210 |
Why?
|
| Chondrosarcoma | 1 | 2023 | 216 | 0.200 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2022 | 112 | 0.200 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2022 | 86 | 0.200 |
Why?
|
| Treatment Outcome | 11 | 2023 | 32848 | 0.200 |
Why?
|
| Liposarcoma | 1 | 2022 | 214 | 0.190 |
Why?
|
| SMARCB1 Protein | 1 | 2020 | 109 | 0.180 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2023 | 297 | 0.180 |
Why?
|
| Torso | 1 | 2020 | 73 | 0.180 |
Why?
|
| Watchful Waiting | 1 | 2021 | 289 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 6207 | 0.160 |
Why?
|
| Extremities | 1 | 2020 | 303 | 0.160 |
Why?
|
| Pyridones | 1 | 2020 | 348 | 0.160 |
Why?
|
| Sulfonamides | 3 | 2021 | 1823 | 0.150 |
Why?
|
| Retrospective Studies | 12 | 2023 | 37905 | 0.150 |
Why?
|
| Ifosfamide | 1 | 2017 | 344 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2022 | 878 | 0.140 |
Why?
|
| Adult | 16 | 2023 | 77950 | 0.140 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 15694 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2016 | 70 | 0.140 |
Why?
|
| Humans | 26 | 2023 | 261506 | 0.140 |
Why?
|
| Lymphocyte Depletion | 1 | 2017 | 264 | 0.140 |
Why?
|
| Osteosarcoma | 1 | 2023 | 929 | 0.130 |
Why?
|
| Pyrimidines | 4 | 2021 | 3518 | 0.130 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 503 | 0.130 |
Why?
|
| Benzamides | 1 | 2020 | 1832 | 0.130 |
Why?
|
| Young Adult | 11 | 2023 | 21445 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2022 | 1411 | 0.130 |
Why?
|
| Allografts | 1 | 2016 | 650 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2023 | 1330 | 0.120 |
Why?
|
| Breast | 1 | 2021 | 1344 | 0.120 |
Why?
|
| Doxorubicin | 2 | 2020 | 3005 | 0.120 |
Why?
|
| Vincristine | 1 | 2017 | 1511 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2017 | 6550 | 0.110 |
Why?
|
| Adolescent | 11 | 2023 | 31252 | 0.110 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 10001 | 0.110 |
Why?
|
| Comorbidity | 1 | 2016 | 2352 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 1546 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 10035 | 0.090 |
Why?
|
| Middle Aged | 12 | 2023 | 86204 | 0.080 |
Why?
|
| Aged | 10 | 2023 | 70117 | 0.080 |
Why?
|
| Anthracyclines | 2 | 2020 | 331 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 3719 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2330 | 0.070 |
Why?
|
| Female | 11 | 2023 | 141928 | 0.070 |
Why?
|
| Prognosis | 3 | 2022 | 21713 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 4757 | 0.070 |
Why?
|
| Male | 12 | 2023 | 123000 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2023 | 29902 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 3976 | 0.060 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 8865 | 0.060 |
Why?
|
| Deoxycytidine | 2 | 2020 | 1353 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 3869 | 0.060 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2016 | 2979 | 0.060 |
Why?
|
| Cyclin B | 1 | 2023 | 63 | 0.060 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2023 | 99 | 0.050 |
Why?
|
| Valine | 1 | 2023 | 176 | 0.050 |
Why?
|
| Carbolines | 1 | 2022 | 27 | 0.050 |
Why?
|
| Genomics | 2 | 2023 | 2738 | 0.050 |
Why?
|
| Child | 5 | 2023 | 29154 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2012 | 2638 | 0.050 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2022 | 119 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2022 | 248 | 0.050 |
Why?
|
| Health Records, Personal | 1 | 2020 | 20 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 11538 | 0.050 |
Why?
|
| Transplantation, Homologous | 2 | 2017 | 2843 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2023 | 619 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2017 | 9180 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2023 | 480 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2023 | 16273 | 0.040 |
Why?
|
| Remission Induction | 2 | 2018 | 3569 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 194 | 0.040 |
Why?
|
| Androgens | 1 | 2022 | 511 | 0.040 |
Why?
|
| Morpholines | 1 | 2020 | 289 | 0.040 |
Why?
|
| Oncogenes | 1 | 2022 | 673 | 0.040 |
Why?
|
| Animals | 3 | 2022 | 59536 | 0.040 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 2796 | 0.040 |
Why?
|
| beta Catenin | 1 | 2022 | 688 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 160 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 1021 | 0.040 |
Why?
|
| Recurrence | 2 | 2018 | 4758 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2023 | 755 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 2588 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 756 | 0.040 |
Why?
|
| Nucleocytoplasmic Transport Proteins | 1 | 2016 | 22 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 6915 | 0.040 |
Why?
|
| Copper-transporting ATPases | 1 | 2016 | 44 | 0.040 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2016 | 132 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2016 | 86 | 0.030 |
Why?
|
| Patient Selection | 1 | 2023 | 2055 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 486 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 334 | 0.030 |
Why?
|
| Cation Transport Proteins | 1 | 2016 | 199 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 593 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2023 | 1664 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 419 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2016 | 347 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2018 | 2307 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2022 | 14551 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 435 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2016 | 501 | 0.030 |
Why?
|
| Time Factors | 2 | 2018 | 12926 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2023 | 2488 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2022 | 3821 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 582 | 0.030 |
Why?
|
| Pyrazines | 1 | 2016 | 495 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 2291 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 1519 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 1313 | 0.030 |
Why?
|
| Mutation | 2 | 2023 | 15179 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 1987 | 0.030 |
Why?
|
| Pyrroles | 1 | 2016 | 576 | 0.030 |
Why?
|
| Risk Factors | 2 | 2020 | 17523 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 1681 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2016 | 785 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 1869 | 0.030 |
Why?
|
| Sirolimus | 1 | 2016 | 814 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 5047 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2018 | 1824 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 3552 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 4298 | 0.020 |
Why?
|
| Imidazoles | 1 | 2016 | 999 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 4314 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2018 | 2054 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 2450 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 1121 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 5377 | 0.020 |
Why?
|
| Texas | 1 | 2020 | 6311 | 0.020 |
Why?
|
| Quality of Life | 1 | 2023 | 4532 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2017 | 2238 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 12221 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 1870 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2016 | 3251 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 14889 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 13310 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2023 | 10331 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 4367 | 0.010 |
Why?
|
| United States | 1 | 2020 | 15433 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 5178 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2012 | 9244 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 34495 | 0.010 |
Why?
|